Using pasireotide to treat advanced synovial sarcoma and desmoplastic small round cell tumor

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This clinical trial evaluates the efficacy of pasireotide, a somatostatin analog, as a maintenance treatment for patients with advanced desmoplastic small round cell tumor (DSRCT) and synovial sarcoma (SySa). The study focuses on patients aged 13 to 50 years who have shown stable disease or response after standard treatments and have high expression of specific somatostatin receptors. Participants will receive pasireotide via intragluteal injection every 28 days, and the trial aims to assess progression-free survival and overall survival rates. The study will also analyze measurable residual disease before, during, and after treatment.

Why it matters

Who can join: the full rules

Inclusion Criteria:

Patients meeting all of the following criteria are considered for enrolment into the trial:

1. Reference pathological proven diagnosis of DSRCT in any stage; or Reference pathological proven diagnosis of SySa, IRS III, metastatic or relapsed disease
2. High SSTR2/3/5 mRNA expression, as determined by RNA sequencing in the DKFZ/NCT/DKTK MASTER (ClinicalTrials.gov ID: NCT05852522) or INFORM programs.
3. Stable disease, partial or complete response after completion of standard treatment
4. Age from 13 to 50 years
5. For patients (≥16 years): Karnofsky-Index ≥ 80% For patients (\<16 years): Lansky-Index ≥ 80%
6. No curative treatment option
7. Bodyweight ≥ 30kg and BSA ≥ 1.1m²
8. Time from last chemotherapy (at least 2 chemotherapy cycles) to enrollment \<8 weeks
9. Ability of patient to understand character and individual consequences of the clinical trial
10. Written informed consent (for individuals \<18 years of age an ICF for adolescents and their parents is needed)
11. For women of childbearing potential negative urine pregnancy test at screening as well as highly effective forms of contraception have to be in place thereafter

    * Evidence of childbearing potential is defined as fertile, following menarche and until becoming post-menopausal unless permanently sterile
    * Postmenopausal or evidence of non-childbearing status is defined as:

      * Amenorrhea for 1 year or more without an alternative medical cause following cessation of exogenous hormonal treatments plus follicle stimulating hormone (FSH) levels in the postmenopausal range in women not using hormonal contraception or hormonal replacement therapy.
      * Chemotherapy-induced menopause
      * Surgical sterilization (bilateral oophorectomy, bilateral salpingectomy, total hysterectomy or tubal ligation at least 6 weeks before IMP treatment)
    * A man is considered fertile after puberty unless permanently sterile by bilateral orchidectomy
12. Female patients of childbearing potential and male patients with partners of childbearing potential who are sexually active must agree to the use of two forms of contraception in combination (male condom and one highly effective method). These should be started immediately after signing the informed consent form and continued throughout the period of study treatment plus 3 months for female and male patients . Male patients should refrain from fathering a child or donating sperm during the trial and for at least 3 months following the last dose.
13. Adequate bone marrow, renal, and hepatic function defined by laboratory tests within 14 days prior to study treatment:

    * Hemoglobin ≥ 10 g/dl
    * Neutrophil count ≥ 1,500/mm3
    * Platelet count ≥ 100,000/µl
    * Bilirubin ≤ 1.5 x upper limit of normal (ULN)
    * ALT and AST ≤ 2.5 x ULN
    * Alkaline phosphatase ≤ 2.5 x ULN
    * PT-INR/PTT ≤ 1.5 x ULN
    * Albumin ≥ 25 g/l
    * Creatine kinase ≤ 2.5 x ULN
    * Serum creatinine \< or = 1.5 mg/dl or creatinine clearance = or \> 51 ml/min (calculation according to Crockroft-Gault)

Exclusion Criteria:

Patients presenting with any of the following criteria are not included in the trial:

1. History of hypersensitivity to the investigational medicinal product or to any drug with similar chemical structure or to any excipient present in the pharmaceutical form of the investigational medicinal product
2. Concurrent or previous treatment within 30 days in another interventional clinical trial / Participation in other ongoing clinical trials.
3. Uncontrolled concurrent disease, in particular diabetes mellitus
4. Bleeding disorder
5. Therapeutic anticoagulation which cannot be paused temporarily in order to ensure safe intramuscular injection
6. Is taking or requiring any of the prohibited medication listed in Table 5 (6.4.2)
7. Heart rate at rest \< 60/min
8. fasting glucose level \> 110mg/dl
9. Severe neurologic or psychiatric disorder
10. Pregnancy/lactation
11. Prior treatment with somatostatin analog

    \-

Where it's running

• National Center for Tumour Diseases, University Hospital Heidelberg
  Heidelberg, Baden-Wurttemberg, Germany Recruiting
• Klinikum Stuttgart- Olga Hospital Zentrum für Kinder-, Jugend und Frauenmedizin
  Stuttgart, Baden-Wurttemberg, Germany Not yet recruiting
• Klinikum Stuttgart Studienzentrale Stuttgart Cancer Center, Tumorzentrum Eva-Mayr-Stihl
  Stuttgart, Baden-Wurttemberg, Germany Not yet recruiting
• Universitätsklinikum Essen Pädiatrische Hämatologie und Onkologie
  Essen, North Rhine-Westphalia, Germany Not yet recruiting

Study contacts

• Principal investigator: Richard F. Schlenk, Professor — National Center for Tumour Diseases, University Hospital Heidelberg
• Study coordinator: Richard F. Schlenk, Professor
• Email: richard.schlenk@nct-heidelberg.de
• Phone: +49 (0)6221 56 6228

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Alpha/beta T‑Cell and B‑Cell Depletion plus Zoledronic Acid for Pediatric and Young Adult Solid Tumors

  This study will try removing alpha/beta T cells and B cells from donor stem cell grafts and giving zoledronic acid to see if it helps children and young adults (6 months to 25 years) with relapsed or high‑risk solid tumors tolerate allogeneic transplant and reduce relapse.

  Recruiting Phase 1/2 University of Florida · Gainesville, Florida · NCT06625190

• MASCT-I plus doxorubicin and ifosfamide as first-line treatment for advanced soft tissue sarcoma

  This trial will test whether adding MASCT-I to standard chemotherapy (doxorubicin and ifosfamide) helps adults with advanced soft tissue sarcoma respond better or live longer.

  Recruiting Phase 2 HRYZ Biotech Co. · Guangzhou · NCT06277154

• Lurbinectedin plus irinotecan for advanced desmoplastic small round cell tumor

  This study will try lurbinectedin combined with irinotecan in people 15 and older whose desmoplastic small round cell tumor has come back or spread after anthracycline chemotherapy.

  Recruiting at 6 sites Phase 2 Italian Sarcoma Group · Candiolo, Torino and 10 other locations · NCT07328425

• N-803 for progressive synovial sarcoma and myxoid/round cell liposarcoma after TCR-T therapy

  This trial tests whether N-803 can safely boost lingering TCR-T immune cells and help people whose synovial sarcoma or myxoid/round cell liposarcoma has progressed after prior TCR-T treatment.

  Recruiting Early Phase 1 Northwestern University · Chicago, Illinois · NCT07261657

• ACTengine IMA203 plus mRNA-4203 for cutaneous melanoma and synovial sarcoma

  This trial tests whether giving the ACTengine IMA203 T‑cell therapy together with the mRNA‑4203 vaccine is safe and helps people with HLA‑A*02:01 unresectable or metastatic cutaneous melanoma or synovial sarcoma who have had prior treatment.

  Recruiting at 4 sites Phase 1 Immatics US, Inc. · San Francisco, California and 3 other locations · NCT06946225

• Combining immune therapy with chemotherapy for advanced soft tissue sarcoma

  This study is testing if combining a new immune therapy with standard chemotherapy can help people with advanced soft tissue sarcoma who can’t have surgery or radiation feel better and live longer.

  Recruiting Phase 2 Fudan University · Shanghai, Shanghai Municipality · NCT06849986

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.